drugset / Trial / NCT00827892

Safety of Pioglitazone for Hematoma Resolution In Intracerebral Hemorrhage

NCT00827892

RandomizedParallel-groupQuadruple-blindTreatment

Summary

Intracerebral hemorrhage (ICH) is a devastating disease with less than 20% of survivors being independent at 6 months. There is currently no approved treatment for ICH which has been shown to improve outcomes. In an effort to develop a new treatment for ICH, this research focuses on a different aspect of ICH treatment which has not yet been evaluated: enhancing absorption of the blood clot with medication.

Timeline

Start
2009-03
Primary completion
2013-04
Completion
2013-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Pioglitazone Small molecule 30 mg Oral